Facebook Instagram X-twitter Linkedin Youtube Spotify Apple

Clinical Trials

For a quick look at enrolling or soon to be enrolling investigational drug studies in Duchenne and their enrollment criteria, check out our Clinical Trial Cheat Sheet below.
Clinical Trial Cheat Sheet

Clinical Trial Finder

Use this Clinical Trial Finder below that can help provide you with more information regarding clinical trials in Duchenne that that you, your child, or your patient may be eligible for!

Watch Jett Foundation's Mini Satellite Presentation

Emerging Therapies for Duchenne Muscular Dystrophy

Presented by Jean Mah, M.D., Associate Professor of Pediatric Neurology Alberta Children’s Hospital at the 2016 Child Neurology Society Meeting to learn more about these potential therapies!

Latest Duchenne News

October 7, 2026

Satellos Announces Completion of Enrollment in BASECAMP Phase 2 Clinical Trial of Forazapadin for Duchenne Muscular Dystrophy

At the end of September, Satellos Biosciences announced that enrollment is complete for BASECAMP, a Phase 2 clinical trial evaluating forazapadin, a drug candidate designed to support muscle repair and...
Read More
September 29, 2026

Secretome Therapeutics Announces Initiation of THRIVE-2 Phase 2 Clinical Study Evaluating STM-01 in Duchenne Muscular Dystrophy

Today, Secretome Therapeutics announced that its Phase 2 clinical study, THRIVE-2, has opened for enrollment at participating clinical sites across the United States. The study will evaluate the safety and...
Read More
September 18, 2026

Sarepta Therapeutics Announces Recipients of the 9th Annual Route 79, The Duchenne Scholarship Program

On September 8, 2026, Sarepta Therapeutics announced the recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 academic year. Each recipient will receive a scholarship of up to...
Read More
September 11, 2026

ITF Therapeutics Highlights DUVYZAT Access and the Publication of a New Plain Language Summary

Today, ITF Therapeutics shared an update on its efforts to expand access to information, data, and treatment for the Duchenne community, including the publication of a new Plain Language Summary...
Read More
September 10, 2026

Novartis Announces FDA Acceptance of Delpacibart Zotadirsen Biologics License Application for Priority Review in DMD44

Novartis recently announced that the U.S. Food and Drug Administration has accepted its application for priority review of delpacibart zotadirsen, an investigational treatment for people with Duchenne muscular dystrophy who...
Read More
August 24, 2026

Precision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD Study

Precision BioSciences has dosed the first patient at Arkansas Children’s Hospital, a PPMD Certified Duchenne Care Center and designated MDA Care Center, in the Phase 1/2 Function-DMD clinical trial evaluating...
Read More